AOBiome was founded by Jamie Heywood in 2012.

Who are AOBiome's investors?

AOBiome's investors include Wakestream Ventures.

How much funding has AOBiome raised?

AOBiome has disclosed $3.1M raised across 2 rounds.

Where is AOBiome headquartered?

AOBiome is headquartered in Cambridge, US.

AOBiome

Cambridge, US · Founded 2012 · 18 employees on LinkedIn · 1 known investors

Find your way into AOBiome

294 people in our graph share verified history with the AOBiome team — schools, employers, funds. One of them is your warm intro.

Adrianna Maunlockedknows Jamie Heywood · together at Massachusetts Institute of Technology (overlapped)

×10knows the team · via Massachusetts Institute of Technology

knows the team · via Harvard Medical School and Massachusetts General Hospital

AOBiome Therapeutics is a late-stage biotechnology company developing microbiome-based treatments for inflammatory skin conditions such as atopic dermatitis and pruritus. Its lead candidate, B244, uses a single strain of Ammonia Oxidizing Bacteria to moderate immune response by simultaneously down-regulating multiple inflammatory markers (IL-4, IL-5, IL-13, IL-31).

Biotech Digital Health Healthtech Wellness & Fitness

Founders & leadership

AOBiome was founded in 2012 by Jamie Heywood.

Jamie Heywood in 𝕏Co-Founder & Board Member, Former CEO and ChairmanJamie Heywood studied mechanical engineering at MIT and has worked on drug discovery through ALS TDI, co-founded PatientsLikeMe, and currently holds a role at Alden Scientific involving proteomics and machine learning research.

Spiros Jamas inFounding CEO2013–2021Spiros Jamas holds a Doctor of Science in Biotechnology from MIT and has held CEO or founder roles at multiple biopharmaceutical companies including Entera Bio, Tempero Pharmaceuticals, Enanta Pharmaceuticals, and Alpha-Beta Technology, with prior experience as a healthcare analyst at State Street Global Advisors.

Todd KruegerinChief Executive Officer, President and Director

Board

Leonard BarshackManager of Issuer

Walter ThompsonManager of Issuer

Investors · 1

Wakestream VenturesGrand Rapids · $150K – $500K

Reported raises · per SEC filings

Form D private placements

$3.1M disclosed across 2 rounds · 2014–2015

▶$2.5MraisedSep 2015 · 2 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Leonard BarshackDirector
Spiros JamasExecutive Officer, Director
James HeywoodDirector
Walter ThompsonDirector

Offering amount: $15M
Amount sold: $2.5M
First sale: Sep 2015
Incorporated: Limited Liability Company, Delaware, 2012
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$576.5KraisedAug 2014 · 13 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

James HeywoodExecutive Officer, Director
Spiros JamasExecutive Officer
Walter G. ThompsonDirector
Leonard BarshackDirector

Offering amount: $7.5M
Amount sold: $576.5K
First sale: Aug 2014
Incorporated: Limited Liability Company, Delaware, 2012
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

3 people who came through AOBiome went on to found or lead other companies.

Klaus DugiNon Executive DirectorFounded Vandria Jasmina AganovicGeneral Manager of Consumer ProductsFounded Arcaea Elsa JungmanProduct ManagerFounded HelloBiome

Competitors · 1

by search overlap

Mission BioCapital Platinum Program Holdings LLC18 shared keywordsMission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.

Companies competing with AOBiome for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does AOBiome do?: AOBiome Therapeutics is a late-stage biotechnology company developing microbiome-based treatments for inflammatory skin conditions such as atopic dermatitis and pruritus. Its lead candidate, B244, uses a single strain of Ammonia Oxidizing Bacteria to moderate immune response by simultaneously down-regulating multiple inflammatory markers (IL-4, IL-5, IL-13, IL-31).
Who founded AOBiome?: AOBiome was founded by Jamie Heywood in 2012.
Who are AOBiome's investors?: AOBiome's investors include Wakestream Ventures.
How much funding has AOBiome raised?: AOBiome has disclosed $3.1M raised across 2 rounds.
Where is AOBiome headquartered?: AOBiome is headquartered in Cambridge, US.